Compare Becton Dickinson and Co (BDX) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs SAP SE — how do they compare? Becton Dickinson and Co trades at $156.46 (market cap $41.51B), while SAP SE trades at $158.8 (market cap $181.79B). The key difference: SAP SE is far larger — about 4.4× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | SAP | |
|---|---|---|
Market Cap | $41.51B | $181.79B |
Sector | Health | Technology |
52-Week High | $185.39 | $308.61 |
52-Week Low | $135.49 | $148.06 |
Enterprise Value | $57.97B | $179.30B |
Dividend Yield | 2.79% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
SAP trades at $159.97, up 1.34% today, with a neutral technical signal and strong profitability metrics including a 19.58% net income margin. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2. Recent news highlights SAP's resolution of EU antitrust concerns and strategic focus on AI investments to drive cloud growth, which now represents over 60% of revenue.
SAP presents a compelling investment case with robust fundamentals and analyst consensus pointing to significant upside, but faces risks from competitive pressures and execution challenges in its AI transition. The stock's current valuation below consensus price targets suggests potential for appreciation if cloud and AI initiatives deliver expected growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
